Cargando…
Targeted therapeutic effect against the breast cancer cell line MCF-7 with a CuFe(2)O(4)/silica/cisplatin nanocomposite formulation
The combination of magnetic nanoparticles with a porous silica is a composite that has attracted significant attention for potential multifunctional theranostic applications. In this study, 30 wt % CuFe(2)O(4) was impregnated into a matrix of monodispersed spherical hydrophilic silica (HYPS) nanopar...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Beilstein-Institut
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880833/ https://www.ncbi.nlm.nih.gov/pubmed/31807407 http://dx.doi.org/10.3762/bjnano.10.214 |
_version_ | 1783473836160712704 |
---|---|
author | Jermy, B Rabindran Ravinayagam, Vijaya Alamoudi, Widyan A Almohazey, Dana Dafalla, Hatim Hussain Allehaibi, Lina Baykal, Abdulhadi Toprak, Muhammet S Somanathan, Thirunavukkarasu |
author_facet | Jermy, B Rabindran Ravinayagam, Vijaya Alamoudi, Widyan A Almohazey, Dana Dafalla, Hatim Hussain Allehaibi, Lina Baykal, Abdulhadi Toprak, Muhammet S Somanathan, Thirunavukkarasu |
author_sort | Jermy, B Rabindran |
collection | PubMed |
description | The combination of magnetic nanoparticles with a porous silica is a composite that has attracted significant attention for potential multifunctional theranostic applications. In this study, 30 wt % CuFe(2)O(4) was impregnated into a matrix of monodispersed spherical hydrophilic silica (HYPS) nanoparticles through a simple dry impregnation technique. The chemotherapy drug cisplatin was loaded through electrostatic equilibrium adsorption over 24 h in normal saline solution. The presence of cubic spinel CuFe(2)O(4) on HYPS was confirmed through powder X-ray diffraction (PXRD), Fourier transform infrared spectroscopy (FTIR) and diffuse reflectance UV–vis spectroscopy (DR UV–vis) analysis. The HYPS particles showed a surface area of 170 m(2)/g, pore size of 8.3 nm and pore volume of 0.35 cm(3)/g. The cisplatin/CuFe(2)O(4)/HYPS nanoformulation showed the accumulation of copper ferrite nanoparticles on the surface and in the pores of HYPS with a surface area of 45 m(2)/g, pore size of 16 nm and pore volume of 0.18 cm(3)/g. Transmission electron microscopy (TEM) and energy dispersive X-ray (EDX) mapping analysis showed the presence of homogeneous silica particles with nanoclusters of copper ferrite distributed on the HYPS support. Vibrating sample magnetometry (VSM) analysis of CuFe(2)O(4)/HYPS showed paramagnetic behavior with a saturated magnetization value of 7.65 emu/g. DRS UV–vis analysis revealed the functionalization of cisplatin in tetrahedral and octahedral coordination in the CuFe(2)O(4)/HYPS composite. Compared to other supports such as mesocellular foam and silicalite, the release of cisplatin using the dialysis membrane technique was found to be superior when CuFe(2)O(4)/HYPS was applied as the support. An in vitro experiment was conducted to determine the potential of CuFe(2)O(4)/HYPS as an anticancer agent against the human breast cancer cell line MCF-7. The results show that the nanoparticle formulation can effectively target cancerous cells and could be an effective tumor imaging guide and drug delivery system. |
format | Online Article Text |
id | pubmed-6880833 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Beilstein-Institut |
record_format | MEDLINE/PubMed |
spelling | pubmed-68808332019-12-05 Targeted therapeutic effect against the breast cancer cell line MCF-7 with a CuFe(2)O(4)/silica/cisplatin nanocomposite formulation Jermy, B Rabindran Ravinayagam, Vijaya Alamoudi, Widyan A Almohazey, Dana Dafalla, Hatim Hussain Allehaibi, Lina Baykal, Abdulhadi Toprak, Muhammet S Somanathan, Thirunavukkarasu Beilstein J Nanotechnol Full Research Paper The combination of magnetic nanoparticles with a porous silica is a composite that has attracted significant attention for potential multifunctional theranostic applications. In this study, 30 wt % CuFe(2)O(4) was impregnated into a matrix of monodispersed spherical hydrophilic silica (HYPS) nanoparticles through a simple dry impregnation technique. The chemotherapy drug cisplatin was loaded through electrostatic equilibrium adsorption over 24 h in normal saline solution. The presence of cubic spinel CuFe(2)O(4) on HYPS was confirmed through powder X-ray diffraction (PXRD), Fourier transform infrared spectroscopy (FTIR) and diffuse reflectance UV–vis spectroscopy (DR UV–vis) analysis. The HYPS particles showed a surface area of 170 m(2)/g, pore size of 8.3 nm and pore volume of 0.35 cm(3)/g. The cisplatin/CuFe(2)O(4)/HYPS nanoformulation showed the accumulation of copper ferrite nanoparticles on the surface and in the pores of HYPS with a surface area of 45 m(2)/g, pore size of 16 nm and pore volume of 0.18 cm(3)/g. Transmission electron microscopy (TEM) and energy dispersive X-ray (EDX) mapping analysis showed the presence of homogeneous silica particles with nanoclusters of copper ferrite distributed on the HYPS support. Vibrating sample magnetometry (VSM) analysis of CuFe(2)O(4)/HYPS showed paramagnetic behavior with a saturated magnetization value of 7.65 emu/g. DRS UV–vis analysis revealed the functionalization of cisplatin in tetrahedral and octahedral coordination in the CuFe(2)O(4)/HYPS composite. Compared to other supports such as mesocellular foam and silicalite, the release of cisplatin using the dialysis membrane technique was found to be superior when CuFe(2)O(4)/HYPS was applied as the support. An in vitro experiment was conducted to determine the potential of CuFe(2)O(4)/HYPS as an anticancer agent against the human breast cancer cell line MCF-7. The results show that the nanoparticle formulation can effectively target cancerous cells and could be an effective tumor imaging guide and drug delivery system. Beilstein-Institut 2019-11-12 /pmc/articles/PMC6880833/ /pubmed/31807407 http://dx.doi.org/10.3762/bjnano.10.214 Text en Copyright © 2019, Jermy et al. https://creativecommons.org/licenses/by/4.0https://www.beilstein-journals.org/bjnano/termsThis is an Open Access article under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0). Please note that the reuse, redistribution and reproduction in particular requires that the authors and source are credited. The license is subject to the Beilstein Journal of Nanotechnology terms and conditions: (https://www.beilstein-journals.org/bjnano/terms) |
spellingShingle | Full Research Paper Jermy, B Rabindran Ravinayagam, Vijaya Alamoudi, Widyan A Almohazey, Dana Dafalla, Hatim Hussain Allehaibi, Lina Baykal, Abdulhadi Toprak, Muhammet S Somanathan, Thirunavukkarasu Targeted therapeutic effect against the breast cancer cell line MCF-7 with a CuFe(2)O(4)/silica/cisplatin nanocomposite formulation |
title | Targeted therapeutic effect against the breast cancer cell line MCF-7 with a CuFe(2)O(4)/silica/cisplatin nanocomposite formulation |
title_full | Targeted therapeutic effect against the breast cancer cell line MCF-7 with a CuFe(2)O(4)/silica/cisplatin nanocomposite formulation |
title_fullStr | Targeted therapeutic effect against the breast cancer cell line MCF-7 with a CuFe(2)O(4)/silica/cisplatin nanocomposite formulation |
title_full_unstemmed | Targeted therapeutic effect against the breast cancer cell line MCF-7 with a CuFe(2)O(4)/silica/cisplatin nanocomposite formulation |
title_short | Targeted therapeutic effect against the breast cancer cell line MCF-7 with a CuFe(2)O(4)/silica/cisplatin nanocomposite formulation |
title_sort | targeted therapeutic effect against the breast cancer cell line mcf-7 with a cufe(2)o(4)/silica/cisplatin nanocomposite formulation |
topic | Full Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880833/ https://www.ncbi.nlm.nih.gov/pubmed/31807407 http://dx.doi.org/10.3762/bjnano.10.214 |
work_keys_str_mv | AT jermybrabindran targetedtherapeuticeffectagainstthebreastcancercelllinemcf7withacufe2o4silicacisplatinnanocompositeformulation AT ravinayagamvijaya targetedtherapeuticeffectagainstthebreastcancercelllinemcf7withacufe2o4silicacisplatinnanocompositeformulation AT alamoudiwidyana targetedtherapeuticeffectagainstthebreastcancercelllinemcf7withacufe2o4silicacisplatinnanocompositeformulation AT almohazeydana targetedtherapeuticeffectagainstthebreastcancercelllinemcf7withacufe2o4silicacisplatinnanocompositeformulation AT dafallahatim targetedtherapeuticeffectagainstthebreastcancercelllinemcf7withacufe2o4silicacisplatinnanocompositeformulation AT hussainallehaibilina targetedtherapeuticeffectagainstthebreastcancercelllinemcf7withacufe2o4silicacisplatinnanocompositeformulation AT baykalabdulhadi targetedtherapeuticeffectagainstthebreastcancercelllinemcf7withacufe2o4silicacisplatinnanocompositeformulation AT toprakmuhammets targetedtherapeuticeffectagainstthebreastcancercelllinemcf7withacufe2o4silicacisplatinnanocompositeformulation AT somanathanthirunavukkarasu targetedtherapeuticeffectagainstthebreastcancercelllinemcf7withacufe2o4silicacisplatinnanocompositeformulation |